News Biogen Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 09:46:13 2024-04-26 am EDT			5-day change	1st Jan Change
202 ^USD	-0.24%		+2.94%	-22.68%

Apr. 25	Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA	CI
Apr. 25	Goldman Sachs Adjusts Biogen Price Target to $340 From $393	MT

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®	Apr. 25	GL
Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA	Apr. 25	CI
Goldman Sachs Adjusts Biogen Price Target to $340 From $393	Apr. 25	MT
Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	Apr. 25	MT
Barclays Adjusts Price Target on Biogen to $200 From $215	Apr. 25	MT
HC Wainwright Adjusts Biogen's Price Target to $300 From $325	Apr. 25	MT
Wedbush Adjusts Price Target on Biogen to $215 From $213	Apr. 25	MT
Health Care Down Amid Mixed Earnings -- Health Care Roundup	Apr. 24	DJ
Biogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 24	MT
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET	Apr. 24	DJ
Wall St edges lower as rising yields overshadow upbeat corporate results	Apr. 24	RE
Morgan Stanley Cuts Biogen's Price Target to $331 From $339	Apr. 24	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Apr. 24	MT
Sector Update: Health Care	Apr. 24	MT
Piper Sandler Raises Biogen's Price Target to $335 From $325	Apr. 24	MT
RBC Lowers Biogen's Price Target to $317 From $326	Apr. 24	MT
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET	Apr. 24	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Apr. 24	DJ
Biogen Affirms Guidance After Mixed First Quarter	Apr. 24	MT

No results for this search